RxDoctor Payments Data

Amar Trivedi, MD

Clinical Cardiac Electrophysiology · Loveland, CONPI 1164718433

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (36.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 71.7% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $31,421, 4.5 times the $7,013 reported in 2019.

$81,573in general payments, 2019–2025

Across 338 payments — averaging $241.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$59K
  • Abbott$19K
  • Medical Device Business Services, Inc.$2K
  • Biosense Webster, Inc.$745
  • Boston Scientific$628
  • Biotronik Inc.$610
  • plus $219 from 6 others
$298,466in research payments, 2019–2025

Across 44 payments — averaging $6783.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$298K

What the payments were for

  • Consulting fees$10,35813%
  • Speaking & faculty fees$29,45036%
  • Travel & lodging$29,97937%
  • Food & beverage$11,66414%
  • Education$1230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,573 in reported general payments places this provider in the 80th percentile of 66 clinical cardiac electrophysiology providers in Colorado.

See all clinical cardiac electrophysiology providers in Colorado

Medicare billing

Part B allowed, 2024
$290,278
Medicare patients
3,061
Services billed
5,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban228$299,358
XareltoRivaroxaban86$136,003
MultaqDronedarone Hcl31$46,683
Flecainide Acetate37$1,974
Metoprolol Succinate138$1,655
Amiodarone Hcl67$1,460
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$1,027
SotalolSotalol Hcl16$571
Warfarin Sodium28$343
Metoprolol Tartrate28$324
Carvedilol14$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$25$136,00386 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 66 clinical cardiac electrophysiology providers in Colorado.

Other clinical cardiac electrophysiology in Loveland

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →